• Scientists test G. vaginalis treatment


Scientists test G. vaginalis treatment

Nov 08 2011

Posted by Neil Clark

Scientists have used quantitative analysis processes to determine whether neutralising recombinant antibodies will become a novel treatment for in bacterial vaginosis.

In a study published by BMC Biotechnology journal, a team from Lithuania noted that bacterial vaginosis is often caused by gardnerella vaginalis colonising the vaginal tract, which produces protein toxin vaginolysin (VLY).

Inhibition of VLY-mediated cell lysis by antibodies may have important physiological relevance., with the team suggesting that recombinant single-chain antibodies may have the desired effect.

Using quantitative analysis processes, the scientists tested the antigen-binding activity of purified single-chain variable fragments of immunoglobulins (scFvs) and calculated apparent Kd values and found that the neutralizing potency of scFvs were in agreement with those of parental full-length antibodies.

"G. vaginalis caused infections continue to be a worldwide problem, therefore neutralizing recombinant antibodies may provide novel therapeutic agents useful in the treatment of bacterial vaginosis and other diseases caused by G. vaginalis," the report noted.

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


NGVS 2024

May 23 2024 Beijing, China


May 28 2024 Tel Aviv, Israel


May 28 2024 Leuven, Belgium

PREP 2024

May 28 2024 Philadelphia, PA, USA


May 29 2024 Beijing, China

View all events